Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 73% of modeled bridge. Strengths: Occupancy Rate, Net-to-Gross Ratio. Risks: Commercial Payer %. Risk-adjusted uplift: $9.6M (vs $13.3M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $5.0M | $5.0M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $4.8M | $139K | $5.0M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $773K | $2.3M | $3.1M | $9.7M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $161K | $161K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 29.3% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $1.3M | $2.5M | $3.8M | $5.0M | $5.0M | $5.0M | $5.0M |
| Denial Rate Reduction | $0 | $1.2M | $2.5M | $3.7M | $5.0M | $5.0M | $5.0M | $5.0M |
| A/R Days Reduction | $0 | $1.0M | $2.0M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M |
| Clean Claim Rate | $0 | $81K | $161K | $161K | $161K | $161K | $161K | $161K |
| Cumulative | $0 | $3.6M | $7.2M | $10.7M | $13.3M | $13.3M | $13.3M | $13.3M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $13.3M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 57% / 9.4x | 61% / 10.8x | 65% / 12.2x | 67% / 12.9x | 69% / 13.7x |
| 9.0x | 52% / 8.0x | 56% / 9.3x | 60% / 10.5x | 62% / 11.1x | 64% / 11.8x |
| 10.0x | 47% / 6.9x | 52% / 8.0x | 56% / 9.1x | 58% / 9.7x | 59% / 10.3x |
| 11.0x | 43% / 6.0x | 48% / 7.0x | 52% / 8.0x | 54% / 8.5x | 55% / 9.0x |
| 12.0x | 39% / 5.2x | 44% / 6.1x | 48% / 7.1x | 50% / 7.5x | 52% / 8.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 17% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 5.4x, adding 3.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $23.1M | — | $23.1M | 9.2% |
| Year 1 | $23.8M | +$8.8M | $32.6M | 13.0% |
| Year 2 | $24.5M | +$13.3M | $37.8M | 15.0% |
| Year 3 | $25.3M | +$13.3M | $38.5M | 15.3% |
| Year 4 | $26.0M | +$13.3M | $39.3M | 15.6% |
| Year 5 | $26.8M | +$13.3M | $40.0M | 15.9% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $2.5M | $3.8M | $5.0M | $6.0M |
| Denial Rate Reductio | $2.5M | $3.7M | $5.0M | $6.0M |
| A/R Days Reduction | $1.5M | $2.3M | $3.1M | $3.7M |
| Clean Claim Rate | $81K | $121K | $161K | $193K |
| Total | $6.6M | $9.9M | $13.3M | $15.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 158 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 9.2% | -9.8% | 3.3% | 13.6% | P61 |
| Net-to-Gross | 14.1% | 13.8% | 19.4% | 29.3% | P26 |
| Occupancy | 77.8% | 49.6% | 64.4% | 73.9% | P82 |
| Rev/Bed | $1.4M | $501K | $1.1M | $1.5M | P71 |
| Exp/Bed | $1.3M | $508K | $1.0M | $1.4M | P67 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.